4,150 Shares in PRA Health Sciences Inc (PRAH) Acquired by Salem Investment Counselors Inc.

Salem Investment Counselors Inc. acquired a new stake in PRA Health Sciences Inc (NASDAQ:PRAH) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,150 shares of the medical research company’s stock, valued at approximately $315,000.

Other institutional investors have also made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of PRA Health Sciences by 12.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after buying an additional 160 shares in the last quarter. Carroll Financial Associates Inc. raised its position in PRA Health Sciences by 127.4% during the third quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 790 shares during the period. Comerica Bank purchased a new stake in PRA Health Sciences during the third quarter valued at approximately $214,000. Trustmark National Bank Trust Department purchased a new stake in PRA Health Sciences during the second quarter valued at approximately $225,000. Finally, Aperio Group LLC purchased a new stake in PRA Health Sciences during the second quarter valued at approximately $233,000. Institutional investors and hedge funds own 98.22% of the company’s stock.

Shares of PRA Health Sciences Inc (NASDAQ PRAH) traded up $0.01 on Friday, reaching $91.07. The company’s stock had a trading volume of 300,845 shares, compared to its average volume of 518,219. PRA Health Sciences Inc has a 12 month low of $54.08 and a 12 month high of $92.00. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.01 and a quick ratio of 1.01. The firm has a market cap of $5,770.45, a P/E ratio of 50.88, a P/E/G ratio of 1.57 and a beta of 0.40.

PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Wednesday, October 25th. The medical research company reported $0.88 EPS for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.03. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. The firm had revenue of $494.55 million for the quarter, compared to analysts’ expectations of $477.89 million. During the same period last year, the firm earned $0.64 EPS. The company’s quarterly revenue was up 23.7% on a year-over-year basis. analysts predict that PRA Health Sciences Inc will post 3.2 earnings per share for the current fiscal year.

In related news, Director Matthew P. Young sold 5,115 shares of PRA Health Sciences stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $79.90, for a total value of $408,688.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.10% of the stock is owned by company insiders.

A number of research analysts have recently commented on PRAH shares. Zacks Investment Research raised PRA Health Sciences from a “hold” rating to a “buy” rating and set a $83.00 price objective on the stock in a research note on Tuesday, September 19th. Mitsubishi UFJ Financial Group began coverage on PRA Health Sciences in a report on Friday, December 15th. They set an “overweight” rating and a $102.00 target price for the company. Credit Suisse Group restated an “outperform” rating and set a $90.00 target price (up previously from $84.00) on shares of PRA Health Sciences in a report on Monday, October 16th. BidaskClub upgraded PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Finally, Mizuho initiated coverage on PRA Health Sciences in a report on Thursday, September 21st. They set a “buy” rating and a $82.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $90.46.

ILLEGAL ACTIVITY NOTICE: “4,150 Shares in PRA Health Sciences Inc (PRAH) Acquired by Salem Investment Counselors Inc.” was first posted by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://weekherald.com/2017/12/30/salem-investment-counselors-inc-takes-position-in-pra-health-sciences-inc-prah.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply